ProMIS Neurosciences (PMN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 19, 2026.
Voting matters and shareholder proposals
Election of seven directors to serve until the next annual meeting or until successors are elected.
Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval of an amendment to the 2025 Stock Option and Incentive Plan.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Seven nominees listed for director positions, including Eugene Williams, Neil Cashman, Joshua Mandel-Brehm, Maggie Shafmaster, Neil K. Warma, William Wyman, and Slanix Alex.
Latest events from ProMIS Neurosciences
- Phase 1b Alzheimer's trial fully enrolled; key data and platform validation expected this year.PMN
Guggenheim Securities Emerging Outlook: Biotech Summit 202613 Apr 2026 - Shareholders will vote on board elections, auditor ratification, and expanding the stock option plan.PMN
Proxy filing9 Apr 2026 - Up to $200M in securities, including $50M ATM, to fund neurodegenerative drug development.PMN
Registration filing25 Mar 2026 - PRECISE-AD trial fully enrolled; strong safety, major financing, and top-line data expected 2027.PMN
Q4 202525 Mar 2026 - Biotech registers 13.8M shares for resale after $75.5M private placement to fund clinical trials.PMN
Registration Filing18 Mar 2026 - Phase Ib Alzheimer's trial shows no ARIA cases, with interim results due Q2 next year.PMN
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - Phase 1b Alzheimer’s trial of PMN 310 advances, aiming for safer, more effective outcomes.PMN
Guggenheim SMID Cap Biotech Conference24 Dec 2025 - Up to $50M in securities offered, with $17.99M ATM for clinical and corporate use; high dilution risk.PMN
Registration Filing16 Dec 2025 - 56.5M shares registered for resale after $30.3M private placement to fund neurodegenerative drug trials.PMN
Registration Filing16 Dec 2025